# SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy

> **NCT05586581** · PHASE1,PHASE2 · RECRUITING · sponsor: **Yale University** · enrollment: 70 (estimated)

## Conditions studied

- HIV Associated Neurocognitive Disorder
- HIV Dementia
- HIV Encephalitis
- Healthy

## Interventions

- **DRUG:** SV2A PET
- **DRUG:** TSPO PET

## Key facts

- **NCT ID:** NCT05586581
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-17
- **Primary completion:** 2027-12
- **Final completion:** 2030-12
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-09-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05586581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05586581, "SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05586581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*